In The News Posted October 31, 2019 Share Posted October 31, 2019 MALMÖ, Sweden, Oct. 31, 2019 /PRNewswire/ -- - Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation's (ESOT) Congress... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.